secwatch.observer — SEC 8-K summary
======================================

Issuer:     EXELIXIS, INC. (EXEL)
CIK:        0000939767
Form:       8-K
Filed at:   2025-11-04T23:59:59+00:00
Accession:  0000939767-25-000127
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Exelixis Q3 revenues $597.8M, EPS $0.69; announces $750M stock buyback by 2026
------------------------------------------------------------------------------

- Total revenues $597.8M (+10.8% YoY); cabozantinib US net product rev $542.9M (+13.5% YoY).
- GAAP diluted EPS $0.69 (vs $0.40); Non-GAAP diluted EPS $0.78 (vs $0.47).
- Board authorized $750M stock repurchase program through Dec 31, 2026.
- Restructuring charges $19.8M related to corporate reorganization; plan to close King of Prussia office.
- Zanzalintinib NDA submission planned before year-end based on positive STELLAR-303 colorectal cancer data.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/939767/000093976725000127/0000939767-25-000127-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/939767/000093976725000127/exel-20251104.htm
  HTML page:      https://secwatch.observer/filing/0000939767-25-000127

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer